The approval was based on data from the 2-year phase 3 JUNIPERA study that evaluated secukinumab in pediatric patients aged 2 to 17 years with a confirmed diagnosis of ERA or JPsA.
The approval was based on a comprehensive data package demonstrating that Yusimry was highly similar to the reference product, Humira.
The ongoing phase 3 BE MOBILE 2 study compared the efficacy and safety of bimekizumab to placebo in 332 adults with active ankylosing spondylitis.
The approval was based on data from a phase 3 study which evaluated tofacitinib in adults with active AS who had an inadequate response to at least 2 NSAIDs.
Shortly after an EUA was issued, Genentech announced that tocilizumab (marketed under the brand name Actemra) was in shortage.
Findings showed that treatment with secukinumab resulted in a 72% reduction in the risk of flare at week 104 compared with placebo.
Nicole Bundy, MD, MPH, discusses the need for lifestyle interventions, in addition to pharmacologic treatment, during the management of patients with autoimmune diseases.
Authors of a commentary assessed the role of IL-1 receptor antagonism, specifically anakinra, in the treatment of patients with severe COVID-19.
Data are lacking on the effectiveness of acupuncture in alleviating pain post total knee replacement.
Study demonstrates the impact of lifestyle factors on the inflammatory condition.
